Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux
July 3, 2020 – 6:00 pm CEST Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]
July 3, 2020 – 6:00 pm CEST Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]
Paris (France), June 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
(French only) Regards croisés : Interviews of Judith Greciet, CEO of Onxeo, and Mr Nicolas Trebouta, representing Financière de la […]
Interview of Judith Greciet, CEO of Onxeo, following the entry into the capital of Invus, a long-term renowned investor […]
The funds raised will accelerate the development of Onxeo’s programs, and extend its cash runway into Q1 2022 Paris […]
The Extraordinary General Meeting will be held on June 19, 2020 on the second call Paris (France), May 29, […]
Paris (France), May 27, 2020 – 8.45 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Paris (France), April 27, 2020 – 7.00 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]
Paris (France), May 7, 2020 – 7:30 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]
The Annual General Meeting will be held on May 29, 2020 Paris (France), March 27, 2020 – 8:30 pm CET […]
Paris (France), January 20, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Dowload the press release
Paris (France), December 9, 2019 – 05:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or […]
(in French only) Watch the interview
Settlement agreement fully resolves long-lasting litigation between the parties and all related proceedings Settlement terms have no impact on Onxeo’s […]
Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
The winning project aims to develop a drug candidate in immuno-oncology from the platON™ platform Funding from the French State […]
Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]
Advancing innovation towards breakthrough cancer therapies Paris, April 9, 2018 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ […]
Paris, April 25, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company […]
Advancement of core pipeline assets on track with key development catalysts expected in 2018 First new molecule generated from platON™, […]
January 9-12, 2017 in San Francisco, CA In 2016, Onxeo has achieved a number of significant milestones, positioning the Company […]
Paris (France), Copenhagen (Denmark), – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of […]
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]
Pipeline reinforced through major development milestones on existing assets and new product acquisition Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext […]
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan […]
Clinical development plan in line with objectives Livatag® on track to deliver its next important milestone with 90% of patients […]
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative […]
Exceptional performance linked to international licensing agreements BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and […]
BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today […]
Paris (France), June 19, 2017 – 05:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the […]
Offering upsized in response to investor demand Paris (France), June 20, 2017 – 08:00 am CEST – Onxeo S.A. […]
Sound cash position of €27.7m as at June 30, 2017 and cash runway till Q1 2019 Development of the core […]
Transaction confirms Onxeo’s strategic focus on innovative orphan oncology drugs Paris (France), July 31, 2017 – 05:45 pm CEST – […]
Paris (France), October 17, 2017 – 10 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]
Onxeo Announces its Financial Agenda for 2018 Paris (France), January 23, 2018 – 5:45 pm CET – Onxeo S.A. […]
Paris (France), January 3, 2018 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]
The company posts a profit as a result of an exceptional revenue High potential for further growth Paris, March 3, […]
Paris (France), September 11, 2019 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or “the Company”), […]
Total demand of Approximately 76.4 million euros, i.e. an oversubscription rate of 216% of the offer Full exercise of the […]
Onxeo gains access to AsiDNA compound, a first-in-class signal interfering DNA Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq […]
2015: Successful year of consolidation and major achievements in all lead programs Progression of Phase III trial of Livatag® in […]
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan […]
Transaction reinforces Company’s cash position and proceeds will be fully allocated to the advancement of Onxeo’s pipeline, including its […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]
Drs. Jean-Pierre Kinet of Harvard Medical School, and Jean-Pierre Bizzari, international expert in Oncology, join the Onxeo Board of Directors […]
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announces its […]